Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer1 report from 1 outlet in 1 language · first reported 2026-09-28 12:00 UTC · updated 2026-09-28 12:00 UTC · JSONHealthSparrowprostate cancerReportsLantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate CancerGlobeNewswire — all · en · 2026-09-28 12:00 UTC